From Wikipedia, the free encyclopedia
RG7314 is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of autism. As of August 2014, it is in phase II clinical trials for this indication.
- "Roche - Pipeline". 2014. Retrieved 2014-08-01.
- A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders, at ClinicalTrials.gov; retrieved September 2, 2014
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|